RETRACTED ARTICLE: Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial

Eugenia VispoDepartment of Infectious Diseases Hospital Carlos III, Madrid, Spain

Pablo BarreiroDepartment of Infectious Diseases Hospital Carlos III, Madrid, Spain

Ivana MaidaDepartment of Infectious Diseases Hospital Carlos III, Madrid, Spain

Alvaro MenaDepartment of Infectious Diseases Hospital Carlos III, Madrid, Spain

Francisco BlancoDepartment of Infectious Diseases Hospital Carlos III, Madrid, Spain

Sonia Rodríguez-NovoaPharmacology Unit Hospital Carlos III, Madrid, Spain

Judit MorelloPharmacology Unit Hospital Carlos III, Madrid, Spain

Inmaculada Jimenez-NacherPharmacology Unit Hospital Carlos III, Madrid, Spain

Juan Gonzalez-LahozDepartment of Infectious Diseases Hospital Carlos III, Madrid, Spain

Vincent SorianoDepartment of Infectious Diseases Hospital Carlos III, Madrid, SpainCorrespondence[email protected]

show all

Abstract

This article has been removed from the archive because of a court ruling, pending a final verdict.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

RETRACTED ARTICLE: Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial

Information for

Open access

Opportunities

Help and information

RETRACTED ARTICLE: Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature